Lantheus Medical Imaging, Inc. engages in discovering, developing, and marketing medical imaging agents. Lantheus Medical Imaging has headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada, and Australia. During its history, the company launched the products Cardiolite (Technetium Tc99m Sestamibi Preparation Kit), which has become the gold standard for use in myocardial perfusion imaging, and Definity (perflutren lipid microsphere) for use in suboptimal echocardiograms.
From 2001 to 2008 Lantheus was part of the Bristol-Myers Squibb Medical Imaging, Inc. group.

Ultrasound Contrast Agents:

From Lantheus Medical Imaging.
Activated DEFINITY® Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. The perflutren lipid microspheres exhibit lower acoustic impedance than blood and enhance the intrinsic backscatter of blood.
Echocardiography with Definity produced more detailed images of the heart in difficult-to-image patients versus echocardiography alone, and images obtained with the contrast agent provided a more accurate assessment of segmental wall motion compared with unenhanced images.

See also Coherent Contrast Imaging.

In August 2001 DuPont Pharmaceuticals Company received FDA approval.

Bristol-Myers Squibb Medical Imaging, Inc. was a wholly-owned subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), a pharmaceutical and related health care products company. Bristol-Myers Squibb sold its medical imaging business in 2007 to the private equity firm Avista Capital Partners for $525 million, as part of its effort to focus on its core pharmaceutical pipeline.
Formed in 1956 as New England Nuclear Corporation (NEN), the company grew to become a leader in the field of diagnostic imaging and later evolved through its transition from NEN to DuPont, followed by Bristol-Myers Squibb Medical Imaging (BMS), and finally named Lantheus Medical Imaging.

Founded in 1991, ImaRx Pharmaceutical Corp. designs, develops and markets pharmaceuticals for medical imaging (MRI, ultrasound and computed tomography) for the radiological imaging industry.
ImaRx Pharmaceutical Corp., announced 1999 that it has been acquired by E.I DuPont de Nemours & Co., Inc. The terms of the acquisition provide a royalty-free licensing arrangement with a newly-formed company, ImaRx LLC ('LLC'), to pursue and develop new products and technologies for drug and gene delivery independent from DuPont. Yamanouchi Pharmaceutical Co. Ltd., ImaRx' licensee for Asian territories for this product, will continue to develop the product in Asia as DuPont's licensee. ImaRx LLC will have ownership of all other targeted and therapeutic products previously owned by ImaRx, including imaging products outside of diagnostic ultrasound imaging and two other imaging products, SonoRx® and LumenHance®, which are both FDA approved and licensed to BRACCO Diagnostics.
See also Lantheus Medical Imaging and Definity®.

Ultrasound Contrast Agents: